10-Q: Biodesix Q3 Revenue Jumps 20%, Net Loss Narrows

Biodesix, Inc. reported a 20% increase in total revenue for the third quarter of 2025, driven by strong growth in both diagnostic tests and development services, while also narrowing its net loss.

Summary

• Total revenue for the three months ended September 30, 2025, increased by 20% to $21.8 million, compared to $18.1 million in the prior year period.
• Year-to-date total revenue for the nine months ended September 30, 2025, grew 17% to $59.7 million, up from $50.9 million in the same period of 2024.
• Diagnostic Tests revenue rose 16% to $19.8 million in Q3 2025, primarily due to increased test volumes and higher average revenue per test for Nodify Lung Nodule Risk Assessment.
• Development Services revenue surged 97% to $1.9 million in Q3 2025, reflecting new agreements and delivery against existing contracts.
• Gross margin improved by 400 basis points to 81% in Q3 2025, attributed to revenue growth and optimized testing workflows.
• Net loss for Q3 2025 decreased by 15% to $(8.7) million, compared to $(10.3) million in Q3 2024.
• Year-to-date net loss for 2025 improved by 10% to $(31.3) million, from $(34.7) million in 2024.
• Cash and cash equivalents stood at $16.6 million as of September 30, 2025, a decrease of $4.1 million from June 30, 2025.
• Net cash used in operating activities for the nine months ended September 30, 2025, was $(24.0) million, a $20.6 million decrease in cash used compared to the same period in 2024.
• The company completed a 1-for-20 reverse stock split on September 15, 2025, and subsequently regained compliance with Nasdaq's minimum bid price requirement on September 26, 2025.
• Biodesix drew $10.0 million from the Tranche C loan under the Perceptive Term Loan Facility on May 8, 2025.
• Raised approximately $5.0 million in gross proceeds ($4.8 million net) from the sale of 596,532 common shares through its at-the-market (ATM) program during Q3 2025, with $45.0 million remaining capacity.

Sentiment

Score: 6

Explanation: The company shows strong revenue growth and a narrowing net loss, indicating operational improvements and market traction. However, the negative stockholders' equity, continued reliance on capital raises, and significant regulatory uncertainties surrounding LDTs temper the overall positive sentiment, suggesting a company in a critical growth phase with inherent financial and regulatory challenges.

Positives

• Total revenue increased by 20% in Q3 2025 and 17% year-to-date 2025, demonstrating strong top-line growth.
• Diagnostic Tests revenue grew 16% in Q3 2025, driven by increased test volumes and improved average revenue per test, including a major Medicare Advantage plan restarting payments.
• Development Services revenue nearly doubled in Q3 2025 (97% increase) and grew 68% year-to-date, indicating successful expansion of partnerships and new agreements.
• Gross margin improved by 400 basis points to 81% in Q3 2025, reflecting operational efficiencies and better revenue per test.
• Net loss narrowed by 15% in Q3 2025 and 10% year-to-date 2025, showing progress towards profitability.
• Net cash used in operating activities decreased by $20.6 million year-to-date 2025, indicating improved operational cash flow management.
• Successfully regained compliance with Nasdaq's minimum bid price requirement following a 1-for-20 reverse stock split.
• Secured an additional $10.0 million through the Tranche C loan from the Perceptive Term Loan Facility, extending liquidity.
• Reached patient enrollment requirements for the ALTITUDE study in July 2025, a randomized control study for Nodify CDT and XL2 tests.
• Initiated the CLARIFY clinical study to further confirm the performance of Nodify CDT and Nodify XL2 tests in real-world settings.
• Announced a new Master Collaborative Research Agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) for oncology biomarker assay development.

Negatives

• Cash and cash equivalents decreased by $9.6 million during the nine months ended September 30, 2025, and by $4.1 million from June 30, 2025, to September 30, 2025.
• Total stockholders' (deficit) equity turned negative, reaching $(1.7) million as of September 30, 2025, from $20.9 million at December 31, 2024.
• Accounts receivable increased by $5.2 million from June 30, 2025, to September 30, 2025, impacting working capital and cash flow.
• Operating expenses (excluding direct costs and expenses) increased by 10% in Q3 2025, primarily due to sales and marketing expansion.
• Long-term notes payable increased to $47.1 million as of September 30, 2025, from $36.4 million at December 31, 2024, increasing debt burden.
• The company continues to incur significant net losses, despite improvements.
• The company received a Nasdaq delisting notice on March 24, 2025, due to minimum bid price non-compliance, although compliance was later regained.

Risks

• Inability to achieve or sustain profitability.
• Difficulty in attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies for diagnostic tests.
• Challenges in managing growth, which could disrupt operations.
• Failure to retain sales and marketing personnel, or to increase sales and marketing capabilities to drive revenue growth.
• Failure to maintain current relationships or enter into new relationships with biopharmaceutical companies.
• Significant fluctuations in operating results, potentially causing performance to fall below expectations or guidance.
• Issues with product performance and reliability affecting business growth.
• Vulnerability to supply problems and price fluctuations due to reliance on third-party and single-source suppliers.
• Negative impact on business, financial condition, and results of operations from pandemics, natural disasters, or similar events.
• Adverse effects on relationships with providers and reputation due to failure to offer high-quality support for diagnostic tests.
• Inability to continue to innovate and improve diagnostic tests and services.
• Security or data privacy breaches or other unauthorized access to information systems.
• Significant disruptions in information technology systems.
• Incurrence of substantial liabilities and limitations on marketing/sale of diagnostic tests due to product liability lawsuits.
• Inability to compete successfully with competition from many sources, including larger companies.
• Performance issues, service interruptions, or price increases by shipping carriers.
• Material adverse effect on sales and profitability from cost-containment efforts of customers, purchasing groups, and integrated delivery networks.
• Potential effects of litigation and other proceedings.
• Negative impact on global economic conditions, financial markets, and business from general economic and financial market conditions, including enhanced U.S. tariffs, import/export restrictions, or other trade barriers.
• Inability to attract and retain key personnel.
• Current and future debt financing placing restrictions on operating and financial flexibility.
• Need to raise additional capital to fund existing operations, develop platforms, commercialize new diagnostic tests, or expand operations.
• Acquisition of other businesses potentially requiring significant management attention, disrupting business, diluting stockholder value, and adversely affecting results of operations.
• Uncertainty of insurance coverage and reimbursement status of newly approved diagnostic tests.
• Future healthcare reform measures hindering or preventing commercial success of diagnostic tests.
• Compliance with anti-corruption, anti-bribery, anti-money laundering, and similar laws, as well as healthcare fraud and abuse laws.
• Ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements that will be accepted by the market in a timely manner.
• Failure to comply with ongoing FDA or other domestic and foreign regulatory authority requirements, or unanticipated problems with diagnostic tests, leading to restrictions or market withdrawal.
• Future product recalls.
• Legal proceedings initiated by third parties alleging intellectual property infringement, misappropriation, or violation.
• Volatility of the trading price of common stock.
• No assurance that common stock will maintain compliance with Nasdaq minimum bid price or other listing standards.
• Inaccurate estimates or judgments relating to critical accounting policies causing operating results to fall below expectations.
• Adverse effects from a prolonged federal government shutdown, particularly if it interrupts Medicare, Medicaid, or other federally funded healthcare programs.
• Uncertainty regarding FDA regulation of laboratory developed tests (LDTs) as medical devices, despite a recent court decision vacating the FDA's final rule, as Congress or future administrations could still impose new regulatory frameworks.

Future Outlook

The company expects research and development expenses to increase as it continues to innovate and develop additional products and expand data management resources. Sales and marketing expenses are also projected to increase with the expansion of the sales force and marketing activities. While these expenses are expected to increase in absolute dollars, they are anticipated to decrease as a percentage of revenue in the long term. The company is evaluating new accounting guidance on income tax disclosures and disaggregation of income statement expenses, with no material impact expected from the credit losses standard. The INSIGHT study participants are expected to complete follow-up by 2026, and LG Chem plans to launch ficlatuzumab by 2028 if approved.

Management Comments

• We believe that establishing a new standard of care utilizing personalized diagnostics requires a deep understanding of clinical needs, scientific expertise to develop tests using the optimal technology for each clinical question, development of clinical evidence to demonstrate benefits of the testing, a scalable operational infrastructure, and an established commercial channel to drive market adoption and payer coverage.
• We continuously revisit our technology strategy and roadmap to integrate new technologies into our evolving offering, which ultimately support the addition of new service and product revenue offerings.
• We believe that no single technology can interrogate the complexity of the human disease state to help solve all clinical questions. For that reason, we employ a multi-omic approach to solving diagnostic challenges.
• While our Development Services revenue continues to grow, it is important to note that we benefit from these partnerships in ways that expand beyond revenue. We are continuously expanding our knowledge and biological understanding of multiple diseases and the rapidly evolving treatment and regulatory approval landscape.
• We plan to continue investing in the field sales force through select expansion and provide them with tools that maximize their education and selling efforts in order to achieve greater returns.

Industry Context

The diagnostic solutions industry is characterized by continuous innovation, particularly in multi-omic approaches combining genomics, proteomics, and AI for personalized diagnostics. The company's focus on lung cancer diagnostics aligns with a growing demand for early detection and personalized treatment guidance. The regulatory landscape for Laboratory Developed Tests (LDTs) remains uncertain, with the FDA attempting to increase oversight, though recent court decisions have challenged this. This regulatory flux creates both risk and potential for companies that can adapt to evolving standards. The company's collaborations with academic centers like MSK and biopharmaceutical partners are consistent with industry trends towards collaborative research and development to accelerate product pipelines and market adoption.

Comparison to Industry Standards

• The company's multi-omic approach, combining genomics, proteomics, and AI, is a leading-edge strategy in the diagnostic industry, aiming to provide comprehensive insights beyond single-technology tests. This positions it favorably against competitors relying on more traditional, singular diagnostic methods.
• The established average turnaround times for the company's lung diagnostic tests (1-5 business days) are competitive within the industry, offering physicians timely results for critical treatment decisions, which is a key differentiator in patient care compared to slower, more complex testing platforms.
• The company's extensive clinical research, resulting in over 90 peer-reviewed publications, demonstrates a strong commitment to evidence-based diagnostics, a benchmark for credibility and adoption in the medical community, comparable to leading diagnostic developers like Guardant Health or Exact Sciences.
• The collaboration with Memorial Sloan Kettering Cancer Center (MSK) for novel molecular minimal residual disease (MRD) tests and oncology biomarker assays aligns with industry best practices of partnering with top-tier academic institutions to drive innovation and clinical validation, similar to partnerships seen with Foundation Medicine or Caris Life Sciences.
• The company's ability to attract over 65 industry clients and academic partners for its Development Services indicates a strong reputation and capability in supporting biopharmaceutical and life sciences companies, a competitive advantage in a market where specialized diagnostic development expertise is highly valued.

Corporate Governance

Legal Proceedings

• Not presently a party to any legal proceedings that, if determined adversely, would individually or taken together have a material adverse effect on business, results of operations, financial condition, or cash flows.

Stakeholder Impact

• Shareholders: Experienced a 1-for-20 reverse stock split and regained Nasdaq compliance, which may stabilize stock price and maintain market access. However, the company's total stockholders' equity turned negative, indicating increased financial risk.
• Employees: Benefited from the initiation of discretionary employer matching contributions to the 401(k) plan in 2025. Increased headcount in research and development, and sales and marketing functions, indicates growth opportunities.
• Customers (Healthcare Providers): Benefit from improved diagnostic tests, faster turnaround times (1-5 business days), and ongoing clinical studies (ALTITUDE, CLARIFY) aimed at expanding evidence and utility of tests.
• Customers (Biopharmaceutical/Life Sciences): Benefit from expanding Development Services, new agreements, and collaborative research (e.g., with MSK) for diagnostic test development.
• Creditors (Perceptive Credit Holdings IV, LP): The company drew an additional $10.0 million Tranche C loan and remains in compliance with all restrictive and financial covenants associated with its borrowings, indicating continued adherence to debt obligations.

Next Steps

• Continue to monitor and manage the INSIGHT study, with participant data being monitored and sites closed throughout 2025, and study follow-up expected to complete by 2026.
• Proceed with the CLARIFY clinical study, collecting patient outcomes and clinical information on up to 4,000 patients to confirm Nodify CDT and Nodify XL2 test performance.
• Continue collaboration with Memorial Sloan Kettering Cancer Center (MSK) under the new Master Collaborative Research Agreement (MCRA) for developing oncology biomarker assays.
• Manage the remaining $45.0 million capacity under the 2024 At-The-Market (ATM) Program for potential future equity financing.
• Monitor the impact of the One Big Beautiful Bill Act (OBBBA) on income tax disclosures, with the guidance becoming effective for interim periods beginning January 1, 2026.
• Evaluate the impact of ASU 2024-03 on disaggregation of income statement expenses, which becomes effective for annual periods beginning January 1, 2027.
• Monitor the evolving regulatory landscape for Laboratory Developed Tests (LDTs) following the vacating of the FDA's May 2024 rule, and any potential future legislative or administrative actions.

Key Dates

Recommendation

While Biodesix demonstrates strong revenue growth (20% in Q3) and a narrowing net loss, indicating positive operational momentum and market acceptance for its diagnostic tests and development services, several factors warrant a 'hold' recommendation. The company's total stockholders' equity has turned negative, signaling a precarious financial position. It continues to rely on capital raises, as evidenced by the $10.0 million Tranche C loan and ongoing ATM program, to fund operations and growth. Furthermore, the regulatory environment for Laboratory Developed Tests (LDTs) remains highly uncertain, despite a recent court decision vacating the FDA's rule, posing a significant long-term risk to its core business. The increase in accounts receivable also suggests potential working capital strain. Investors should monitor the company's path to profitability, cash flow generation, and the evolving regulatory landscape before considering a stronger position.

Keywords

Diagnostic Solutions, Lung Cancer, Blood-based Tests, Nodify Lung, GeneStrat, VeriStrat, Biopharmaceutical Services, Proteomics, Genomics, SEC Filing, 10-Q, Financial Results, Revenue Growth, Net Loss, Cash Flow, Nasdaq Compliance, Reverse Stock Split, Perceptive Term Loan, ATM Program, Clinical Trials, LDT Regulation, Healthcare Diagnostics